[PRESS RELEASE] – EDMONTON, Alberta, July 23, 2026 – Safari Flower Co., a wholly owned subsidiary of Aurora Cannabis Inc., announced the receipt of European Union Good Manufacturing Practice (EU-GMP) certification for its Ontario facility, solidifying its ability to serve international medical cannabis markets. The certification is granted for a three-year term and validates Safari Flower Co.'s unwavering commitment to meeting the highest international standards for quality, compliance and operational excellence.
"We are incredibly proud to achieve the highest level of EU-GMP certification, which reinforces our position as a trusted cultivator and manufacturer of high-quality medical cannabis for international markets," Safari CEO Brigitte Simons said. "This milestone reflects the strong culture of compliance, quality and operational excellence embedded across our facility, and the trusted partnerships required to serve regulated supply chains. It further positions Safari to support the evolving needs of medical cannabis markets globally."
Safari's facility is a 59,000-square-foot cultivation and manufacturing site in the Niagara Region of Ontario, Canada, with a history of EU-GMP accreditations and exporting operations. Aurora acquired the Safari Flower Co. in April 2026 to provide incremental EU-GMP capacity to align with the company's existing global manufacturing network and to support supply of high-quality medical cannabis to international markets including Germany, Poland and the U.K.
As international medical cannabis markets continue to evolve, EU-GMP certification remains a critical enabler of Safari's ability to serve regulated markets with confidence. The company is proud to be a trusted supplier of high-quality medical cannabis to markets that require rigorous quality, safety and compliance standards and to meet rapidly evolving patient demand.
